Regeneron Pharmaceuticals, Inc.
Common Stock · NASDAQ
Live TMS charts are coming soon.
Paper trading. Simulated, no real money.
No public theses on REGN yet. When TMS traders open paper trades on it and make their thesis public, the long and short split, average conviction and hit rate show here.
Key stats load once market data is connected.
The FDA reportedly approved a myasthenia gravis therapy tied to Regeneron and Alnylam, according to the headline only. The item gives no further detail on the product or the companies' statements.
No SEC financials for REGN yet. Companies that file 10-K and 10-Q reports show revenue, earnings, cash flow and the balance sheet here.
Source: SEC filings (10-K, 10-Q).
Paper trading only. Nothing here is financial advice.